<div class="headers"><div>Fig. 2  Proportion of patients achieving HAQ response over time by baseline symptom duration in each treatment arm: a abata-cept + MTX, b abatacept monotherapy, c MTX monotherapy. Error bars represent 95% CI. HAQ response is deﬁned as a reduction of at least 0.30 units from baseline. HAQ H ealth Assessment Question-naire; MTX methotrexate</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>1(A)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Fig. 2  Proportion of patients achieving HAQ response over time by baseline symptom duration in each treatment arm: a abata-cept + MTX, b abatacept monotherapy, c MTX monotherapy. Error bars represent 95% CI. HAQ response is deﬁned as a reduction of at least 0.30 units from baseline. HAQ H ealth Assessment Question-naire; MTX methotrexate</p></td>
</tr>
</tbody>
</table>
